Joël has more than 30 years of experience in the Biotech and the Pharma industry. He has been the cofounder and CEO of InnaVirVax, a French biotech that developed a candidate therapy for HIV infection up to phase 2 clinical trial. Joël has had various positions in several biotech companies (Genetica, AP cells, Neurotech and Alfact Innovation) and in the Pharma (Rhone-Poulenc Rorer now part of Sanofi Aventis) and has been involved actively in 5 different drug candidates studied in the clinic, up to phase 3. Scientific by training, Joël is a co-author of more than 60 peer reviewed publications and 30 patent families in various therapeutic fields.
Joël is graduated from AgroParisTech and holds a PhD from Université de Paris.
Management team
Scientific Advisor
Director of Research 1st class at the CNRS, directing the multidisciplinary Chemistry & Biology, Modeling & Immunology for Therapy (CBMIT) team within the CNRS and the Université de Paris
Board Of Directors
Scientific Advisory Board
Director of Research 1st class at the CNRS, directing the multidisciplinary Chemistry & Biology, Modeling & Immunology for Therapy (CBMIT) team within the CNRS and the Université de Paris
Chief Executive Officer of the Institute for Research in Immunology and Cancer at the University of Montréal
Professor of Target and Systems Biochemistry at the Faculty of Science of the Vrije Universiteit Amsterdam
